The unseen suffering of CIDP

You may not see it, but many patients with CIDP continue to experience debilitating symptoms that often require burdensome treatments.1-3

argenx is committed to discovering innovative solutions.

Explore emerging evidence

CIDP=chronic inflammatory demyelinating polyneuropathy.

Patient portrayal

CIDP can be debilitating to patients’ lives3,4

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, often progressive, immune-mediated neuromuscular disorder of the peripheral nervous system.5-7

CIDP results in motor and sensory impairment in the upper and lower limbs. CIDP significantly impacts quality of life.6,8

Patients experience a range of disabling mobility and sensory issues, even with treatment.9,10

Common motor and sensory signs and symptoms

Frequent tripping or falling11

Difficulty rising from a seated position11

Fine motor function impairment11

Neuropathic pain and fatigue12,13

Existing treatments, while beneficial, may fall short in the fight against CIDP

Low rate of remission

 

~20%

of patients on available treatments achieve remission (CDAS=2)9*†

Treatment burden

 

~85%

of patients require ongoing treatment with potentially burdensome therapies1

Residual symptoms

 

~88%

of treated patients report residual neurological symptoms9†‡

*Remission (CDAS=2) defined as stable and off treatment for <5 years. Seventeen patients (15%) achieved cured disease activity status (CDAS=1), defined as stable and off treatment for ≥5 years.9,14
†A cross-sectional study of 112 patients in the Netherlands with a confirmed CIDP diagnosis from patient files and expert consensus using the 2010 EFNS/PNS criteria. At study entry, median age was 62 years, median disease duration was 9 years, and median time from onset to diagnosis was 5 months (2-12 months). Eighty percent of patients presented with typical CIDP, and 20% presented with CIDP variants.9
‡Residual neurological symptoms included muscle weakness (73%), sensory symptoms (77%), pain (52%), and fatigue (77%).9

CDAS=CIDP Disease Activity Status; CIDP=chronic inflammatory demyelinating polyneuropathy; EFNS=European Federation of Neurological Societies; PNS=Peripheral Nerve Society.

IVIG, corticosteroids, and PLEX are effective therapies and are the guideline-recommended treatments for CIDP

Both short- and long-term effectiveness and risks need to be considered with all treatments6

Current CIDP treatments are broadly immunosuppressive or immunomodulatory and are associated with safety concerns1,15:

In some patients, IVIG therapies may cause serious side effects (eg, venous thrombosis, hemolytic anemia, aseptic meningitis, and renal complications)1,15

In some cases, long-term use of steroids for CIDP is associated with a range of potential side effects, including weight gain, hyperglycemia, hypertension, osteoporosis, cataracts, and increased risk for infection16

CIDP=chronic inflammatory demyelinating polyneuropathy; IVIG=intravenous immunoglobulin; PLEX=plasma exchange.

Patient portrayal

patients with cidp face safety tradeoffs

Managing CIDP with current therapies can be burdensome for patients, caregivers, physicians, and office staff

Long IV infusion times
3-5 hours per session2

Variable response
Nature of disease and fluctuating response to treatment contribute to challenges managing CIDP9,17-19

Absenteeism*
Many patients with self-reported CIDP missed work or school due to treatment administration20

Venous access issues*†
Treatment interruptions due to difficulty administering20

*Based on a self-reported, online-global GBS|CIDP Foundation survey from 595 adult patients with CIDP (n=222, stratified “likely” based on
patient-reported symptoms). The survey was provided to US-based members (n=475) of the database between 11/13/2017-12/12/2017 and
non-US-based members (n=120) between 1/5/2018-3/26/2018. The survey consisted of 56 questions that gathered information about
demographics, symptoms, work and social activities, and treatment history.20
†Twelve percent of respondents reported treatment interruptions on at least 1 occasion due to inadequate venous access.20
CIDP=chronic inflammatory demyelinating polyneuropathy.

Shining Through CIDP

Supporting patients suffering from CIDP is central to argenx.

Direct your patients and their caregivers to Shining Through CIDP, where they can find reliable information, helpful tips, and relatable stories from people living with CIDP.

References: 1. Bunschoten C et al. Lancet Neurol. 2019;18:784-94. doi.org/10.1016/S1474-4422(19)30144-9 2. Allen JA et al. J Neurol Sci. 2020;408:1-7. doi.org/10.1016/j.jns.2019.116497 3. Ryltoft AK et al. Acta Neurol Scand. 2020;00:1-4. doi:10.1111/ane.13322 4. Bozovic I et al. J Neurol. 2017;264(12):2481-2486. doi:10.1007/s00415-017-8658-x 5. Broers MC et al. Neuroepidemiology. 2019;52:161-172. doi:10.1159/000494291 6. Van den Bergh PYK et al. Eur J Neurol. 2021;28:3556-3583. doi:10.1111/ene.14959 7. Brun S et al. Immuno. 2022;2:118-131. doi.org/10.3390/immuno2010009 8. Querol L et al. J Neurol. 2021;268(10):3706-3716. doi:10.1007/s00415-020-09998-8 9. Bunschoten C et al. J Peripher Nerv Syst. 2019;24:253-259. doi:10.1111/jns.12344 10. Hafsteinsdottir B, Olafsson E. Eur Neurol. 2016;75:263-268. doi:10.1159/000445884 11. Dyck PJB et al. Mayo Clin Proc. 2018;93(6):777-793. doi:10.1016/j.mayocp.2018.03.026 12. Gable KL et al. Muscle Nerve. 2020;1-8. doi:10.1002/mus.27038 13. Michaelides A et al. Pain Ther. 2019;8(2):177-185. doi:10.1007/s40122-019-0128-y 14. Gorson KC et al. J Peripher Nerv Syst. 2010;15:326-333. doi:10.1111/j.1529-8027.2010.00284.x 15. Goyal NA et al. Muscle Nerve. 2021;64:243-254. doi:10.1002/mus.27356 16. Hughes RAC et al. Cochrane Database Syst Rev. 2017;11(11):CD002062. doi:10.1002/14651858.CD002062.pub4 17. Kuitwaard K et al. Eur J Neurol. 2021;28:1677-1683. doi:10.1111/ene.14742 18. Allen JA et al. J Peripher Nerv Syst. 2018;23:78-87. doi:10.1111/jns.12262 19. Adrichem M et al. Brain. 2022;145(5):1641-1652. doi:10.1093/brain/awac054 20. Allen JA et al. Adv Ther. 2021;38:316-328. doi.org/10.1007/s12325-020-01540-6 21. Vermeulen M et al. J Neurol Sci. 1985;70(3):317-326. doi:10.1016/0022-510x(85)90173-x